143 related articles for article (PubMed ID: 8750264)
1. Risk factors for acute graft-versus-host disease in 291 consecutive HLA-identical bone marrow transplant recipients.
Hägglund H; Boström L; Remberger M; Ljungman P; Nilsson B; Ringdén O
Bone Marrow Transplant; 1995 Dec; 16(6):747-53. PubMed ID: 8750264
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
Aschan J; Ringdén O
Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
[TBL] [Abstract][Full Text] [Related]
3. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group.
Jacobsen N; Badsberg JH; Lönnqvist B; Ringdén O; Volin L; Rajantie J; Nikoskelainen J; Keiding N
Bone Marrow Transplant; 1990 Jun; 5(6):413-8. PubMed ID: 2164434
[TBL] [Abstract][Full Text] [Related]
4. Decreased incidence of graft-versus-host disease and improved survival with methotrexate combined with cyclosporin compared with monotherapy in recipients of bone marrow from donors other than HLA identical siblings.
Ringdén O; Klaesson S; Sundberg B; Ljungman P; Lönnqvist B; Persson U
Bone Marrow Transplant; 1992 Jan; 9(1):19-25. PubMed ID: 1543946
[TBL] [Abstract][Full Text] [Related]
5. Predictive factors for chronic graft-versus-host disease after histocompatible sibling donor bone marrow transplantation.
Ochs LA; Miller WJ; Filipovich AH; Haake RJ; McGlave PB; Blazar BR; Ramsay NK; Kersey JH; Weisdorf DJ
Bone Marrow Transplant; 1994 Apr; 13(4):455-60. PubMed ID: 8019471
[TBL] [Abstract][Full Text] [Related]
6. A role of herpes virus serology for the development of acute graft-versus-host disease. Leukaemia Working Party of the European Group for Bone Marrow Transplantation.
Boström L; Ringdén O; Gratama JW; Jacobsen N; Prentice HG; Zwaan FE; Nilsson B
Bone Marrow Transplant; 1990 May; 5(5):321-6. PubMed ID: 2190659
[TBL] [Abstract][Full Text] [Related]
7. Impact of donor and recipient characteristics on the development of acute and chronic graft-versus-host disease following pediatric bone marrow transplantation.
Eisner MD; August CS
Bone Marrow Transplant; 1995 May; 15(5):663-8. PubMed ID: 7670393
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients. Australasian Bone Marrow Transplant Study Group.
Atkinson K; Arthur C; Bradstock K; Dale B; Downs K; Gibson J; Golenia M; Ho J; Joshua D; Juttner C
Bone Marrow Transplant; 1995 Sep; 16(3):401-5. PubMed ID: 8535313
[TBL] [Abstract][Full Text] [Related]
9. Marrow donor immunity to herpes simplex virus: association with acute graft-versus-host disease.
Gratama JW; Sinnige LG; Weijers TF; Zwaan FE; van Heugten JG; Stijnen T; D'Amaro J; The TH; Hekker AC; de Gast GC
Exp Hematol; 1987 Aug; 15(7):735-40. PubMed ID: 3038583
[TBL] [Abstract][Full Text] [Related]
10. Individualized prophylaxis against graft-versus-host disease in leukemic marrow transplant recipients.
Aschan J; Ringdén O; Andström E; Ljungman P; Lönnqvist B; Remberger M
Bone Marrow Transplant; 1994 Jul; 14(1):79-87. PubMed ID: 7951124
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate combined with cyclosporin A decreases graft-versus-host disease, but increases leukemic relapse compared to monotherapy.
Aschan J; Ringdén O; Sundberg B; Gahrton G; Ljungman P; Winiarski J
Bone Marrow Transplant; 1991 Feb; 7(2):113-9. PubMed ID: 2049554
[TBL] [Abstract][Full Text] [Related]
12. Pretransplant herpes virus serology and chronic graft-versus-host disease.
Boström L; Ringdén O; Sundberg B; Ljungman P; Linde A; Nilsson B
Bone Marrow Transplant; 1989 Sep; 4(5):547-52. PubMed ID: 2551436
[TBL] [Abstract][Full Text] [Related]
13. TNF alpha levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD.
Remberger M; Ringden O; Markling L
Bone Marrow Transplant; 1995 Jan; 15(1):99-104. PubMed ID: 7742764
[TBL] [Abstract][Full Text] [Related]
14. Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver?
Klaesson S; Ringdén O; Ljungman P; Aschan J; Hägglund H; Winiarski J
Transplantation; 1995 Dec; 60(11):1225-30. PubMed ID: 8525515
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial comparing use of cyclosporin and methotrexate for graft-versus-host disease prophylaxis in bone marrow transplant recipients with haematological malignancies.
Ringdén O; Bäckman L; Lönnqvist B; Heimdahl A; Lindholm A; Bolme P; Gahrton G
Bone Marrow Transplant; 1986 May; 1(1):41-51. PubMed ID: 3332119
[TBL] [Abstract][Full Text] [Related]
16. Relationship between donor-recipient blood group incompatibility and serum bilirubin after allogeneic bone marrow transplantation from HLA-identical siblings.
Mehta J; Powles R; Horton C; Milan S; Singhal S; Treleaven J
Bone Marrow Transplant; 1995 Jun; 15(6):853-8. PubMed ID: 7581080
[TBL] [Abstract][Full Text] [Related]
17. Graft-versus-host disease in children: the AIEOP-BMT Group experience with cyclosporin A.
Locatelli F; Uderzo C; Dini G; Zecca M; Arcese W; Messina C; Andolina M; Miniero R; Porta F; Rovelli A
Bone Marrow Transplant; 1993 Dec; 12(6):627-33. PubMed ID: 8136746
[TBL] [Abstract][Full Text] [Related]
18. Low incidence of acute GVHD in patients transplanted with marrow from HLA-A,B,DR-compatible unrelated donors among Japanese.
Morishima Y; Kodera Y; Hirabayashi N; Tanimoto M; Matsuyama T; Horibe K; Ohta H; Mizuno S; Morishita Y; Yamauchi T
Bone Marrow Transplant; 1995 Feb; 15(2):235-9. PubMed ID: 7773212
[TBL] [Abstract][Full Text] [Related]
19. Cyclosporine and methylprednisolone after allogeneic marrow transplantation: association between low cyclosporine concentration and risk of acute graft-versus-host disease.
Przepiorka D; Shapiro S; Schwinghammer TL; Bloom EJ; Rosenfeld CS; Shadduck RK; Venkataramanan R
Bone Marrow Transplant; 1991 Jun; 7(6):461-5. PubMed ID: 1873593
[TBL] [Abstract][Full Text] [Related]
20. Factors predicting chronic graft-versus-host disease and survival after marrow transplantation for aplastic anemia.
Niederwieser D; Pepe M; Storb R; Witherspoon R; Longton G; Sullivan K
Bone Marrow Transplant; 1989 Mar; 4(2):151-6. PubMed ID: 2650784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
